Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) Receives Average Recommendation of Buy from Brokerages

Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT – Get Free Report) has been assigned a consensus rating of “Buy” from the nine ratings firms that are presently covering the stock, Marketbeat Ratings reports. Nine equities research analysts have rated the stock with a buy recommendation. The average twelve-month target price among brokers that have issued a report on […]

Related Keywords

China ,Gotham Makker ,Stifel Nicolaus ,Analyst Recommendations For Rocket Pharmaceuticals ,Steward Partners Investment Advisory ,News Ratings For Rocket Pharmaceuticals Daily ,Clearstead Advisors ,Rocket Pharmaceuticals Inc ,Canaccord Genuity Group ,Rocket Pharmaceuticals Trading ,Wells Fargo Company ,Rocket Pharmaceuticals ,Hedge Funds Weigh In On Rocket Pharmaceuticals ,Needham Company ,China Universal Asset Management Co ,Advisor Group Holdings Inc ,Nasdaq ,Securities Exchange Commission ,Get Free Report ,Marketbeat Ratings ,Director Gotham Makker ,Exchange Commission ,Group Holdings ,Partners Investment Advisory ,Universal Asset Management ,Wells Fargo ,Get Free ,Rocket Pharmaceuticals Daily ,Nasdaq Rckt ,Rckt ,Medical ,Ratings ,Consensus ,